Purpose: Patients with persistent or recurrent neutropenic fevers at risk of invasive fungal disease (IFD) are treated empirically with antifungal therapy (AFT). Early treatment using a diagnostic-driven (DD) strategy may reduce clinical and economic burdens. We compared costs and outcomes of both strategies from a UK perspective.
INTRODUCTION
Invasive fungal disease (IFD) is associated with high mortality rates in severely immunocompromised patients, such as those undergoing intensive chemotherapy or stem cell transplantation. 1 IFD results in increased hospital and intensive care unit costs, with pharmacy expenditures (including antifungal treatment) the main cost driver. 2 Because IFD is life-threatening, empirical therapy is commonly used in at-risk patients. 3 With this strategy, patients are treated for suspected IFD when they present with persistent or recurrent neutropenic fevers that are unresponsive to broad-spectrum antibacterial therapy for 72 to 96 hours. Conventional amphotericin B deoxycholate (C-AmB), liposomal amphotericin B (L-AmB), and caspofungin are currently the only antifungal agents licensed for empirical treatment in the setting of persistent or recurrent neutropenic fevers. Empirical treatment can be costly, however, [4] [5] [6] with the potential for overtreatment of nonfungal fever, resulting in increased toxicity and treatment-related costs. 7 Early use of diagnostic assays in a diagnostic-driven (DD) therapy strategy is 1 way to potentially identify patients with invasive aspergillosis (IA) more accurately and, consequently, to better select treatments for these patients. In addition, earlier diagnosis and targeted therapy may reduce costs and improve outcomes by eliminating unnecessary toxic treatment. Several studies have helped us to better understand the clinical impact of a DD strategy compared with a standard empirical strategy. [7] [8] [9] [10] [11] [12] However, these studies do not highlight the economic impact of a DD therapy strategy.
In the present study, we examined the impact on costs and outcomes that may occur in neutropenic patients with a suspected IFD caused by Aspergillus species when treated by using either a typical empirical strategy with antifungal therapy administered to all patients or an early-treatment DD strategy with more targeted antifungal therapy.
PATIENTS AND METHODS
A decision-analytic model was developed to examine the costs and outcomes associated with the standard empirical strategy, in which all patients with persistent or recurrent neutropenic fevers were treated with C-AmB, L-AmB, or caspofungin, compared with a DD strategy, in which selected patients were treated with C-AmB, L-AmB, or voriconazole. Antifungal agents were chosen based on the indications listed in the summaries of product characteristics as well as expert feedback.
The model was developed from a UK perspective and included a time horizon of 5 months. 13 All costs are presented in 2012 British pounds sterling. Costs and outcomes were not discounted because the time horizon was o1 year.
Population
Patients were assumed to be aged Z18 years with hematologic malignancies, undergoing chemotherapy or autologous/allogeneic hematopoietic stem cell transplantation, and expected to be severely neutropenic (neutrophil count o0.5 Â 10 9 cells/L) for Z10 days. [7] [8] [9] [10] [11] [12] Patients could not have had a diagnosis of proven or probable IFD or have received treatment with an investigational antifungal agent in the previous 6 months.
Comparators

DD Strategy
Patients began antifungal therapy when they were suspected of having an IFD based on characteristic lesions on computed tomography scan, Aspergillus species colonization, and/or positive ELISA results for galactomannan antigen (GM) and/or positive results for Aspergillus species on polymerase chain reaction (PCR) assay. Patients were treated with C-AmB, L-AmB, or voriconazole.
Empirical Strategy
Patients began antifungal therapy when they had persistent or recurrent neutropenic fevers that failed to defervesce despite broad-spectrum antibacterial therapy for 72 to 96 hours, with no IFD identified. Patients were treated with C-AmB, L-AmB, or caspofungin.
Model Structure
The decision model (Figures 1AÀ1C) was designed as a standard decision tree, with chance nodes representing the probability of occurrence of each event and decision nodes representing decision points. Patients at risk for IFD, such as those with IA, were entered into the model and were assigned to each strategy as soon as they became neutropenic. At baseline for treatment of initial neutropenic fevers, patients underwent a standard diagnostic evaluation, which included blood cultures, urine cultures, body site-specific microbiologic cultures, serum biochemistry, and hematology studies. After the standard diagnostic evaluation, initial empirical broad-spectrum antibacterial therapy was initiated. Thereafter, other monitoring and microbiologic tests were performed, as clinically appropriate, during the episode of neutropenic fevers. Once persistent or recurrent neutropenic fevers were established, a decision was made to manage them according to the patient's assigned strategy. Patients in the DD strategy group were treated similarly to patients in the empirical strategy group except the former received antifungal prophylaxis with fluconazole, and additional health care resources (eg, GM-ELISA and PCR testing) were used to diagnose IFD. It was assumed that the DD strategy and the empirical strategy were initiated at the same time.
In the DD strategy ( Figure 1B) , an IFD was diagnosed on the basis of clinical and biomarker findings. As a result, patients with a probable or possible diagnosis of IA were treated with appropriate antifungal agents. Patients without a probable or possible diagnosis were not treated with antifungal agents. However, the model structure allowed patients without a confirmed diagnosis of IFD to receive antifungal treatment at the discretion of the clinician while awaiting the outcome of other investigations if an IFD was strongly suspected on clinical grounds. After treatment or no treatment, patients either survived or died (based on the epidemiologic and clinical data obtained from the published literature).
In the empirical strategy ( Figure 1C ), patients were treated with antifungal agents on the basis of persistent or recurrent fevers, regardless of whether the IFD was confirmed to exist. A portion of patients may have had proven or probable IFD, another portion of patients may definitely not have had an IFD, and the remainder of patients may have had an IFD but never had its existence confirmed. After treatment or no treatment, patients either survived or died (based on the epidemiologic and clinical data taken from the published literature).
Model Inputs Incidence
To estimate the costs and outcomes associated with each treatment strategy, the incidence of IFD within a particular clinical setting was required. Within the model, the incidence of IFD was assumed to be 10.9% (95% CI, 9-13), based on a population of patients treated with myelosuppressive chemotherapy for hematologic malignancies or autologous stem cell transplantation in a German tertiary care center. 14 
Clinical Success
Clinical success in the model was assumed to be successful treatment of an IFD and survival of the patient. Ideally, mortality data would be obtained from head-to-head clinical studies. However, available clinical studies have limitations; for example, patients were treated with random mixtures of antifungal agents, and antifungal treatment in the DD strategy was delayed based on study criteria, which may have affected mortality. Furthermore, comparative clinical studies of patients receiving empirical therapy versus DD therapy reported very high overall survival rates for both arms, 8, 9, 11 which made it difficult to estimate the true impact of the treatment strategy on survival.
As a result of these limitations, data from epidemiologic studies were obtained. Mortality was estimated from observations derived from neutropenic patients with hematologic malignancies or who were receiving autologous stem cell transplantation in a German tertiary care center between 2002 and 2006; overall mortality was 10.7% (95% CI, 9-13) and IFD-related mortality was 28.6% (95% CI, 19-39). 13 Assuming that patients without an IFD would not die because of this disease, we assumed that patients with an IFD would have an increase in mortality of 28.6%. Given this assumption, the overall mortality was adjusted to be specific for patients with an IFD (36.2%) and for patients without an IFD (7.6%). 13 also estimated the impact of using nonpolyene antifungal agents (defined as voriconazole and caspofungin) on overall survival. They performed a multivariate analysis for overall survival in patients with IFD and reported that the use of these novel antifungal agents was associated with a significant improvement in overall survival (hazard ratio, 0.589 [95% CI, 0.362-0.959]; P ¼ 0.033). Using these data, the IFD-related and non-IFD-related mortality rates were adjusted to be specific for patients receiving amphotericin-based agents and patients on novel antifungal agents (Supplemental Table I , given in the online version at http://dx.doi.org/ 10.1016/j.clinthera.2015.03.021).
Other assumptions made for clinical success and mortality were that treatment with antifungal agents benefited only those patients with an IFD. Instances of IFD identified by using the DD strategy, but not diagnosed in the empirical strategy, were assumed to occur among patients treated with antifungal agents in the empirical strategy arm; GM-ELISA and PCR tests were assumed to have a sensitivity of 67.7% 15 ; and the empirical strategy only identified 29% to 31% of the IFD confirmed by using the DD strategy. 8, 11 Adverse Events
Adverse events (AEs) in the model were those that occurred in Z10% of patients in the empirical trials [16] [17] [18] and that were deemed to be most resource intensive. As recommended by the key opinion leaders (R. Barnes, R. Herbrecht, O. Morrissey, M. Slavin, E. Bow, J. Maertens, and C. Cordonnier, personal communications, October and November 2012), the AEs were limited to nephrotoxicity, tachycardia, and hypertension. To normalize the percentages to a common population, the percentage of patients experiencing AEs during receipt of caspofungin, voriconazole, or amphotericin B was estimated by applying the absolute difference in AEs seen between each antifungal agent and L-AmB within the respective trials to the pooled AE percentages derived for L-AmB. The proportions of patients experiencing the AEs associated with each antifungal agent are presented in Table I .
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Resource Use and Costs
Health care resources and costs considered in the model were general health care resources used to manage each treatment strategy, antifungal treatment costs, and costs to treat AEs.
General health care resource costs in the model were estimated by using a micro-costing approach. Specifically, resource use for general diagnosis and treatment within an empirical therapy or DD strategy was initially estimated from the published literature 7, 8, 11, 12 and then reviewed by the key opinion leaders (R. Barnes, O. Morrissey, M. Slavin, and J. Maertens, personal communications, November 2012). Patients in the DD strategy used health care resources in a manner similar to those treated via the empirical strategy, except that patients in the DD strategy were also screened for Aspergillus species until they recovered from neutropenia. The health care resources, percentages of patients expected to receive resources, and the mean number of resources patients were expected to use during the treatment strategy are presented in Table II .
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Antifungal agent use for each treatment strategy was obtained from the specific product characteristics 14, [20] [21] [22] [23] and reviewed by the key opinion leaders (R. Barnes, O. Morrissey, M. Slavin, and J. Maertens, personal communications, November 2012). Costing of antifungal agents depended on patient weight. The average patient weight, used to calculate the average unit cost, was estimated as the average weight of men and women in England in 2010 (84.6 kg and 71.2 kg, respectively). 24 The model considered treatment from the point of infection, and antifungal prophylaxis before initiation of empirical therapy was not included. Patients treated with the DD strategy were assumed 1 The difference between C-AmB and L-AmB is estimated. † Defined as a doubling of the serum creatinine level or an increase of at least 88.4 μmol/L if elevated at baseline. 16, 18 to receive antifungal prophylaxis with fluconazole 400 mg/d for 18 days. 8 Mold-active antifungal prophylaxis was not administered to patients in either strategy. Antifungal therapy dosing details, unit costs, and administration costs are presented in Table III. 14, [19] [20] [21] [22] [23] 25 For costing AEs (Table I) 
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Model Calculations
For each treatment strategy, we derived the number of patients treated with antifungal drug therapy, the number of diagnosed IFD, the number of deaths, and costs. The incremental cost per death avoided was calculated as:
Sensitivity Analyses
To test the robustness of model assumptions and parameters, the effect of changing parameters in both ¼ total cost of DD strategy -total cost of empirical strategy ð Þ number of survivors in DD strategy-number of survivors in empirical strategy ð Þ Clinical Therapeutics 1-way and probabilistic sensitivity analyses were examined. Parameters analyzed in 1-way sensitivity analyses included the incidence of IFD, overall and IFD mortality, overall survival hazard ratio, GM-ELISA/PCR test sensitivity, unit costs and probability of AEs, percentage of patients receiving each antifungal agent, duration of antifungal therapy, percentage of patients using each resource, and number of resources used for each antifungal agent within each strategy. The effects of varying individual parameters were examined by using plausible ranges of values from the literature, 95% CIs, or by varying estimates by Ϯ20%. Sensitivity results for each input were ranked from most sensitive to least sensitive and were plotted on a tornado diagram. In addition to 1-way sensitivity analyses, probabilistic sensitivity analyses (second-order Monte Carlo simulation) were also performed. The parameters varied in these analyses and were similar to those in the 1-way sensitivity analyses. We assumed that parameter estimates followed a γ distribution for the following parameters: overall survival hazard ratio, unit costs, duration of antifungal therapy, and number of resources used for each antifungal agent within each strategy. A β distribution was assumed for the incidence of IFD, overall and IFD mortality, GM-ELISA/PCR test sensitivity, probability of AEs, and percentage of patients using each resource. A Dirichlet distribution was assumed for the percentage of patients receiving each antifungal agent within each strategy. Analyses were run 10,000 times to capture stability in the results for each relevant scenario. Scatter plots were developed to represent uncertainty, and cost-effectiveness acceptability curves were created.
RESULTS
Baseline Findings
The number of confirmed IFD in the DD strategy (74 of 1000 at-risk patients) was more than the number of confirmed IFD in the empirical strategy (33 of 1000 at-risk patients). However, the DD strategy was associated with a smaller number of patients who were given antifungal treatment compared with the empirical strategy (74 of 1000 vs 125 of 1000 at-risk patients, respectively). Survival among patients in the DD and empirical strategies were similar: 90.8% and 89.8% of patients, respectively.
Although patients treated according to a DD strategy versus an empirical strategy incurred greater costs due to the use of biomarkers (£27.46 vs £0, respectively), patients treated by using a DD strategy incurred lower overall costs (difference of £740.64) due to the effective use of antifungal agents. As a result, the DD-based treatment strategy was costsaving (ie, costs were less, the strategy prevented more deaths). The baseline results are presented in Table IV . Figure 2 illustrates the sensitivity of the incremental cost per death avoided for the DD strategy versus the empirical strategy. Compared with the empirical strategy, the resulting incremental cost per death avoided was most sensitive to changes in GM-ELISA test sensitivity. Specifically, the DD strategy remained less costly and more effective in preventing death when GM-ELISA test sensitivity approached its lower limit. Results were somewhat sensitive to changes in the relative increase in the number of patients treated in the empirical versus DD strategy, incidence of IFD, and the duration of treatment with L-AmB in the empirical arm. However, despite changes in these parameters within their plausible ranges, the DD strategy was still cost-saving. Changes in all other parameters did not affect the results (ie, the DD strategy remained less costly while avoiding more deaths than the empirical strategy). Figure 3 shows the resulting scatter plot of a DD strategy compared with an empirical strategy. In this analysis, assuming that the distribution of antifungal treatment in the different strategies does not change, the DD strategy was found to be less costly while preventing more deaths (ie, runs of the model with results falling within quadrant 4) 90.16% of the time. The incremental cost per death avoided was £30,000 or less (ie, runs of the model with results falling below the dotted diagonal line within quadrant 1 and quadrant 4) 99.24% of the time. Owing to the possible variability in the hazard ratios for overall survival for newer antifungal agents, many of the simulations fell within the second (0.14%) and third (5.91%) quadrants, where the DD strategy was either more costly and less effective in preventing death or less costly but did not prevent enough deaths to be worth the lower cost.
Sensitivity Analysis
DISCUSSION
In this analysis, we compared the economic impact of using a DD strategy with an empirical strategy for the management of patients with persistent or recurrent neutropenic fevers at risk of IFD. To the best of our knowledge, this study is the first conducted to evaluate the economic impact of a DD strategy on the management of IFD, including suspected IA. According to the results of our analysis, we estimated that $41% fewer AE ¼ adverse event; GM ¼ galactomannan; PCR ¼ polymerase chain reaction; IFD ¼ invasive fungal disease. * Higher "other" medical costs were incurred in the DD strategy due to the use of additional health care resources such as computed tomography scans, abdominal echography, bronchoscopy, and bronchoalveolar lavage.
Incremental Cost Per Death Avoided (£)
Upper limit Lower limit -£450 -£400 -£350 -£300 -£250 -£200 -£150 0 -£50 -£100 GM test sensitivity (base, 67.67%; lower limit, 41.00%; upper limit, 95.00%) Relative increase in number of patients treated in empirical versus DD approach (base, 1.70; lower limit, 1.03; upper limit, 2.36) IFD incidence using empirical therapy approach (base, 10.90%; lower limit, 9.00%; upper limit, 13.00%) IFD incidence using DD approach (base, 10.90%; lower limit, 9.00%; upper limit, 13.00%) Duration of treatment with liposomal amphotericin B (3 mg/kg/day) (empirical arm) (base, 23.33; lower limit, 14.19; upper limit, 32.48) IFD-related mortality (base, 28.57%; lower limit, 19.00%; upper limit, 39.00%) Duration of treatment with liposomal amphotericin B (3 mg/kg/day) (DD arm) (base, 23.33; lower limit, 14.19; upper limit, 32.48)
Duration of treatment with caspofungin (70-mg loading dose on day 1 followed by 50 mg QD) (empirical arm) (base, 28.00; lower limit, 17.02; upper limit, 38.98)
Per-day cost postloading dose of caspofungin (50 mg QD) (base, £327.67; lower limit, £199. patients would be treated with antifungal agents in a DD strategy compared with an empirical strategy. As a result, we were able to avoid more AEs caused by antifungal treatment in already immunocompromised patients. In addition, survival was found to be similar for both the DD and empirical strategies and was consistent with survival rates reported in published clinical studies, 8, 9, 12 despite the fact that survival data were derived from a retrospective medical record extraction study. 13 Overall, given the reduced use of antifungal agents, the total cost of the DD strategy was reportedly lower than that of the empirical strategy, despite the additional costs of GM-ELISA and/or Aspergillus species PCR testing. The costs of GM-ELISA and PCR testing were more than offset by lower antifungal treatment costs as a result of more targeted therapy. The findings of this analysis suggest that the DD strategy may be cost-saving for patients who are neutropenic and have persistent or recurrent unexplained fevers.
One key factor of this analysis will affect the overall savings that may be experienced by a given center; that is, the incidence of IFD that occurs within the center's population. This incidence varies not only between centers due to the environment but also depending on the case-mix of the patients within any given center. High-risk patients will have a greater risk of IFD than lower risk patients. The incidence assumed within this study was derived from a population of patients treated with myelosuppressive chemotherapy or autologous stem cell transplantation for hematologic malignancies in a German tertiary care center. 13 Other centers that treat a greater proportion of high-risk patients may derive even greater cost savings from a DD strategy.
Another limitation of this analysis is the exclusion of prophylaxis with the azole posaconazole. Prophylaxis with posaconazole could influence treatment options and cost savings for patients at high risk of IFD but was not considered in this model because the data to support the outcomes were not available.
An important limitation of this analysis is that patients who are at risk for fungal disease are a heterogeneous population. These patients have different underlying conditions that result in large variability in overall mortality rates. As a result, outcomes of the analyses may vary greatly between patient subpopulations. However, sensitivity analyses found that overall mortality was not a large driver of costs. This is in keeping with overall survival being relatively high, as was also seen in the clinical trials of the DD strategy. 8, 9, 11, 12 Another limitation of this analysis is that the incidence, survival, and efficacy data were not obtained from a single head-to-head clinical trial but were instead obtained from a retrospective cohort study of patients treated with myelosuppressive chemotherapy or autologous stem cell transplantation for hematologic malignancies in a German tertiary care center. 13 A number of clinical studies have assessed the outcomes of the DD and empirical strategies. [7] [8] [9] [10] [11] [12] However, it is difficult to draw conclusions about the potential economic impact of the ideal application of these 2 strategies because heterogeneous treatment regimens and DD strategies were used in the clinical studies. In addition, in 1 study, a delay in the use of antifungal agents within the DD strategy occurred due to study inclusion criteria, and this delay may have affected mortality rates. 8 The timing of the implementation of a DD therapy strategy is important because it may determine how effective the strategy will be in providing early treatment compared with an empirical strategy. A major limitation of the present study was the assumption that the use of a DD strategy would detect IFD, such that treatment for these diseases could occur just as early as empirical treatment. Because DD strategy studies were administered with the criterion that patients must be neutropenic for at least 4 to 5 days, it is unknown whether clinical outcomes for a DD strategy when IFD is identified earlier differ from those of a DD strategy when an IFD is identified later. Additional clinical studies will be important to fully understand the impact of this limitation and whether earlier treatment of IFD improves outcomes.
Overall, untreated IA is associated with high mortality rates. 27 As a result, use of a broad empirical strategy has historically been the standard treatment approach to attempt to alleviate physicians' concerns that some cases of IFD may be missed. Our analysis found that the DD strategy with targeted treatment may be considered a cost-saving alternative to the empirical strategy, while maintaining a similar overall survival rate. Future head-to-head studies collecting economic data will be important to confirm these analyses. 
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